1Post graduate student, Department of Biohemistary, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
2Professor and HOD, Department of Biohemistary, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
3Professor, Department of Biohemistary, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
4Associate Professor, Department of Pathology, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India
Online published on 25 January, 2018.
Biomarkers are useful for early detection of breast cancer by screening and for monitoring cancer status in patients during and after anticancer treatment as tumor markers. Especially Her-2/neu, Ki-67, p53 and the steroid receptors (estrogen receptor ER, progesterone receptor PR), have gained increasing interest.
To find ER, PR, Her2neu, expression and correlation
100 histologically confirmed female breast cancer patients in the age group of 18–80 years were recruited. Information on patient's age, menopausal status, disease stage, clinical nodes were noted from the case files.
The histopathological grading of the breast carcinoma was done according to the Nottingham modification of the Bloom Richardson grading system. IHC was performed by using antibodies against the ER, PR, Her2neu,
52 patients belonged to the molecular class Luminal A and were ER+ve and Her-2/neu negative, 22 patients belonged to the molecular class Luminal B and were ER +ve and showed overexpression of Her-2/neu. 16 patients were triple negative and did not express ER, PR and Her-2/neu. 10 patients overexpressed Her-2/neu and did not express ER. No significant correlation was seen between ER and Her-2/neu, and PR and Her-2/neu expression.
Breast Cancer, Her-2/neu, ER, PR, tumor markers
